drugset / Trial / NCT00141505
PK Effects of Bifeprunox & Valproate in Bipolar I
Phase 2
Completed
Solvay Pharmaceuticals
H. Lundbeck A/S · collabWyeth is now a wholly owned subsidiary of Pfizer · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
The study is to evaluate the effect of bifeprunox on the pharmacokinetics of valproate in subjects with Bipolar I Disorder after multiple dose administration.
Timeline
- Start
- 2005-02
- Primary completion
- 2006-12
- Completion
- 2006-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bifeprunox | Small molecule | — | — |